Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03311308 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03311308 · ClinicalTrials.gov record · last posted 2026-06-30

A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

Name: A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma — clinical trial record (NCT03311308)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorYana Najjar

Started2018-02-07

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to evaluate the effectiveness and safety of the combination of Pembrolizumab (KEYTRUDA®) and the investigational drug, Metformin.

Amendment record 17 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 17 times since 2017-10-09; most recent amendment 2026-06-26. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-06-26

Status change Recruiting→Active, Not Recruitingv17

2018-01-05

Status change Not Yet Recruiting→Recruitingv2

Trial Details

NCT Number	NCT03311308
Lead Sponsor	Yana Najjar Collaborators: Merck Sharp & Dohme LLC
Conditions	Advanced Melanoma
Enrollment	23 participants
Start Date	2018-02-07
Primary Completion	2028-01-31 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-30